HOME >> BIOLOGY >> NEWS
When combining new oral anti-cancer agents with standard chemotherapy, timing may be crucial

(NEW ORLEANS) -- Timing may be everything when it comes to combining the new-generation oral, molecularly targeted anti-cancer agents with standard chemotherapy drugs, UC Davis Cancer Center researchers reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

"Many of the new molecularly targeted anti-cancer agents work by inhibiting cancer cell division and growth -- but in doing so, the new agents could diminish the effectiveness of chemotherapy, which depends on rapid cell cycling," said senior investigator Paul Gumerlock, professor of hematology/oncology at UC Davis Cancer Center. "Because of this, it could be very important in what sequence the new agents are combined with standard chemotherapy drugs."

To test the notion, Gumerlock and his colleagues focused on a new oral epidermal growth factor receptor inhibitor known as erlotinib. Recently, several large clinical trials have compared standard chemotherapy alone to standard chemotherapy plus an oral EGFR inhibitor like erlotinib in the treatment of non-small cell lung cancer. Little if any benefit was found from the addition of an EGFR inhibitor in these trials, in which the EGFR inhibitor and chemotherapy were administered simultaneously.

The UC Davis Cancer Center team set out to determine whether sequential administration would make a difference. The researchers tested erlotinib alone, the standard chemotherapy agent docetaxel alone, the two drugs simultaneously, and the two drugs sequentially. All the tests were done in the laboratory using human non-small cell lung cancer cells.

"We predicted that giving docetaxel first, then erlotinib, would be more effective than giving the erlotinib first, giving both drugs simultaneously or giving either drug alone" Gumerlock said. "And that proved to be true."

Docetaxel, a standard first-line chemotherapy drug for non-small cell lung cancer, works in th
'"/>


5-Jun-2004


Page: 1 2 3

Related biology news :

1. Emory researchers map structure of anti-cancer molecule
2. New way to lock DNA-slicing enzyme onto chromosomes could lead to novel anti-cancer drugs
3. Unraveling a protein, researchers uncover mechanics of anti-cancer agent
4. Lycopenes anti-cancer effect linked to other tomato components
5. Hebrew University researcher wins prize for work leading to new anti-cancer drugs
6. Process triggered by some anti-cancer drugs causes tumors in mice, study finds
7. Evolution boosted anti-cancer prowess of a primordial gene
8. Inhibitor of novel cancer target, LPAAT-beta, demonstrates selective anti-cancer effects
9. Researchers elucidate machinery of major anti-cancer target
10. Genetic engineering could salvage once-promising anti-cancer agents
11. Bacteria discovered in cave produce potential anti-cancer drug

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/16/2019)... ... April 16, 2019 , ... ... speakers for two signature events: The 2019 ISPE Biopharmaceutical Manufacturing Conference , ... 20–21 June. Taking place in one of the most influential bio hubs, Boston, ...
(Date:4/9/2019)... ... ... The McLeod Center for Cancer Treatment and Research has been ... conducted by an independent, third-party panel of experts in radiation oncology, patient safety and ... McLeod is the only such cancer center in South Carolina. The hospital also represents ...
(Date:4/4/2019)... ALISO VIEJO, Calif. (PRWEB) , ... April 02, ... ... a leading clinical genetics testing company, will present results demonstrating that RNA genetic ... hereditary cancer genetic testing. This study, awarded as a Top Rated poster, is ...
Breaking Biology News(10 mins):
(Date:3/15/2019)... and ATLANTA (PRWEB) , ... ... ... the acquisition of 100% equity in American Process Inc. and affiliate companies ... the Alpena Biorefinery in Alpena Michigan, the Thomaston Biorefinery and R&D center ...
(Date:3/14/2019)... ... ... The growth in the number and complexity of regulations as well as ... intelligence (RI) systems are not keeping with ... and cheaper. With a diversity of information sources, identifying and analyzing context based intelligence ...
(Date:3/14/2019)... , ... March 14, 2019 , ... ... release announcing that its Canadian partner, the Eye Machine Canada Inc., had been ... Oculus’s pioneering technology for treating Age-Related Macular Degeneration (AMD). , The previous month, ...
(Date:3/14/2019)... (PRWEB) , ... March 13, 2019 , ... ... its 2019 ISPE Europe Biotechnology Conference , taking place in Brussels, Belgium ... biotechnology best practices, technical and operational solutions, and innovative approaches. , “Biopharmaceuticals ...
Breaking Biology Technology:
Cached News: